These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 30178545)

  • 1. Metformin is the key factor in elevated plasma growth differentiation factor-15 levels in type 2 diabetes: A nested, case-control study.
    Natali A; Nesti L; Venturi E; Shore AC; Khan F; Gooding K; Gates PE; Looker HC; Dove F; Goncalves I; Persson M; Nilsson J;
    Diabetes Obes Metab; 2019 Feb; 21(2):412-416. PubMed ID: 30178545
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes mellitus related biomarker: The predictive role of growth-differentiation factor-15.
    Berezin AE
    Diabetes Metab Syndr; 2016; 10(1 Suppl 1):S154-7. PubMed ID: 26482961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive Properties of Biomarkers GDF-15, NTproBNP, and hs-TnT for Morbidity and Mortality in Patients With Type 2 Diabetes With Nephropathy.
    Bidadkosh A; Lambooy SPH; Heerspink HJ; Pena MJ; Henning RH; Buikema H; Deelman LE
    Diabetes Care; 2017 Jun; 40(6):784-792. PubMed ID: 28341782
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted multiple biomarker approach in predicting cardiovascular events in patients with diabetes.
    Resl M; Clodi M; Vila G; Luger A; Neuhold S; Wurm R; Adlbrecht C; Strunk G; Fritzer-Szekeres M; Prager R; Pacher R; Hülsmann M
    Heart; 2016 Dec; 102(24):1963-1968. PubMed ID: 27456261
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
    Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
    Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GDF-15 as a Target and Biomarker for Diabetes and Cardiovascular Diseases: A Translational Prospective.
    Adela R; Banerjee SK
    J Diabetes Res; 2015; 2015():490842. PubMed ID: 26273671
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Preoperative plasma growth-differentiation factor-15 for prediction of acute kidney injury in patients undergoing cardiac surgery.
    Heringlake M; Charitos EI; Erber K; Berggreen AE; Heinze H; Paarmann H
    Crit Care; 2016 Oct; 20(1):317. PubMed ID: 27717384
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The relationship between insulin resistance and the cardiovascular biomarker growth differentiation factor-15 in obese patients.
    Vila G; Riedl M; Anderwald C; Resl M; Handisurya A; Clodi M; Prager G; Ludvik B; Krebs M; Luger A
    Clin Chem; 2011 Feb; 57(2):309-16. PubMed ID: 21164037
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Circulating GDF-15 levels predict future secondary manifestations of cardiovascular disease explicitly in women but not men with atherosclerosis.
    Gohar A; Gonçalves I; Vrijenhoek J; Haitjema S; van Koeverden I; Nilsson J; de Borst GJ; de Vries JP; Pasterkamp G; den Ruijter HM; Björkbacka H; de Jager SCA
    Int J Cardiol; 2017 Aug; 241():430-436. PubMed ID: 28389123
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The impact of GDF-15, a biomarker for metformin, on the risk of coronary artery disease, breast and colorectal cancer, and type 2 diabetes and metabolic traits: a Mendelian randomisation study.
    Au Yeung SL; Luo S; Schooling CM
    Diabetologia; 2019 Sep; 62(9):1638-1646. PubMed ID: 31161347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth Differentiation Factor 15 as a Biomarker in Cardiovascular Disease.
    Wollert KC; Kempf T; Wallentin L
    Clin Chem; 2017 Jan; 63(1):140-151. PubMed ID: 28062617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. GDF-15 Is Associated with Cancer Incidence in Patients with Type 2 Diabetes.
    Pavo N; Wurm R; Neuhold S; Adlbrecht C; Vila G; Strunk G; Clodi M; Resl M; Brath H; Prager R; Luger A; Pacher R; Hülsmann M
    Clin Chem; 2016 Dec; 62(12):1612-1620. PubMed ID: 27756762
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Growth differentiating factor-15 and its association with traditional cardiovascular risk factors: The African-PREDICT study.
    Vermeulen B; Schutte AE; Gafane-Matemane LF; Kruger R
    Nutr Metab Cardiovasc Dis; 2020 Jun; 30(6):925-931. PubMed ID: 32278609
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Age, renal dysfunction, cardiovascular disease, and antihyperglycemic treatment in type 2 diabetes mellitus: findings from the Renal Insufficiency and Cardiovascular Events Italian Multicenter Study.
    Solini A; Penno G; Bonora E; Fondelli C; Orsi E; Trevisan R; Vedovato M; Cavalot F; Cignarelli M; Morano S; Ferrannini E; Pugliese G;
    J Am Geriatr Soc; 2013 Aug; 61(8):1253-61. PubMed ID: 23889588
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Single and multiple cardiovascular biomarkers in subjects without a previous cardiovascular event.
    Pareek M; Bhatt DL; Vaduganathan M; Biering-Sørensen T; Qamar A; Diederichsen AC; Møller JE; Hindersson P; Leósdóttir M; Magnusson M; Nilsson PM; Olsen MH
    Eur J Prev Cardiol; 2017 Oct; 24(15):1648-1659. PubMed ID: 28644092
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Growth differentiation factor 15, a marker of oxidative stress and inflammation, for risk assessment in patients with atrial fibrillation: insights from the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial.
    Wallentin L; Hijazi Z; Andersson U; Alexander JH; De Caterina R; Hanna M; Horowitz JD; Hylek EM; Lopes RD; Asberg S; Granger CB; Siegbahn A;
    Circulation; 2014 Nov; 130(21):1847-58. PubMed ID: 25294786
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Growth differentiation factor-15: a new biomarker in cardiovascular disease.
    Kempf T; Wollert KC
    Herz; 2009 Dec; 34(8):594-9. PubMed ID: 20024638
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The impact of type 2 diabetes on circulating adipokines in patients with metabolic syndrome.
    Schindler K; Vila G; Hoppichler F; Lechleitner M; Luger A; Anderwald C; Hoefler J; Tomasec G; Kautzky-Willer A; Ludvik B
    Obes Facts; 2012; 5(2):270-6. PubMed ID: 22647307
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Growth differentiation factor 15: a novel risk marker adjunct to the EuroSCORE for risk stratification in cardiac surgery patients.
    Heringlake M; Charitos EI; Gatz N; Käbler JH; Beilharz A; Holz D; Schön J; Paarmann H; Petersen M; Hanke T
    J Am Coll Cardiol; 2013 Feb; 61(6):672-81. PubMed ID: 23391200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Value of plasma growth differentiation factor-15 in diagnosis and evaluation of type 2 diabetic nephropathy].
    Li H; Gao F; Xue Y; Qian Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2014 Mar; 34(3):387-90. PubMed ID: 24670455
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.